halothane has been researched along with n-methyl-3,4-methylenedioxyamphetamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Hawryluck, LA; Kraeva, N; Riazi, S; Russell, T; Steel, AC | 1 |
1 review(s) available for halothane and n-methyl-3,4-methylenedioxyamphetamine
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
1 other study(ies) available for halothane and n-methyl-3,4-methylenedioxyamphetamine
| Article | Year |
|---|---|
Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene.
Topics: Anesthetics, Inhalation; Antipsychotic Agents; Body Temperature; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Creatine Kinase; Dantrolene; Disseminated Intravascular Coagulation; Female; Genetic Variation; Hallucinogens; Haloperidol; Halothane; Humans; Multiple Organ Failure; N-Methyl-3,4-methylenedioxyamphetamine; Neuroleptic Malignant Syndrome; Recurrence; Rhabdomyolysis; Ryanodine Receptor Calcium Release Channel; Spectrum Analysis; Young Adult | 2012 |